Ropeg 3 year trial results

[Paul123456]

Good results, encouraging that reduces other mutation ABs as well as JAK2.

As someone with TET2, I’m hoping/assuming this result applies to Pegasys as well.

ash.confex.com/ash/2018/web...

[mammared]

Thanks Paul. This is VERY interesting. Maybe, with this being presented at the ASH in San Diego this year, it will motivate the US to move forward with our trials in a more aggressive way.

Mammared

[MPort]

Thanks Paul. Results like this give us hope. I wonder when it will be available for us. And if the cost will be high.

[Wyebird]

Thank you

[Timjonze]

Been waiting anxiously for these as it seems like a very viable line of defence - thanks for sharing Paul!

[Paul123456 in reply to Timjonze]

Tim

I’m wondering if the big question is how would a three year trial of Ropeg compare with Pegasys? Ropeg apppears better tolerated (now similar to HU albeit only after 3 years) but would Pegasys have comparable haematological/molecular response?

Best Paul

[Bluetop]

Thanks for sharing these promising results

[Purple478273]

Does anyone know if the Ropeg results apply to ET CALr+, or is it limited to PV or Jak2 mutated ET?